IRONWOOD PHARMACEUTICALS, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $24.0M | $880.0K | $-1.00B | $175.1M | $528.4M | $106.2M | $21.5M | $-282.4M |
| Depreciation & Amortization | $1.1M | $1.2M | $1.2M | $1.4M | $1.5M | $2.3M | $5.6M | $3.9M |
| Depreciation | $1.9M | $2.0M | $1.6M | $1.4M | $1.5M | $3.6M | $5.6M | $3.9M |
| Amortization | — | — | — | — | — | — | — | $8.1M |
| Stock-Based Compensation | $17.3M | $29.9M | $32.0M | $27.0M | $22.3M | $31.2M | $31.3M | $40.5M |
| Net Cash from Operating Activities | $127.0M | $103.5M | $183.4M | $273.8M | $261.9M | $168.8M | $10.7M | $-70.9M |
| Investing Activities | ||||||||
| Capital Expenditures | $34.0K | $142.0K | $273.0K | $136.0K | $265.0K | $1.8M | $7.2M | $351.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-34.0K | $-142.0K | $-1.03B | $-136.0K | $-265.0K | $-1.8M | $-11.1M | $88.9M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | $126.4M | $24.1M | — | — | — |
| Net Cash from Financing Activities | $216.0K | $-107.0M | $277.2M | $-237.6M | $-4.6M | $18.5M | $-1.2M | $30.1M |
| Net Change in Cash | $126.9M | $-3.6M | $-565.8M | $36.1M | $257.1M | $185.5M | $-1.6M | $48.1M |
| Free Cash Flow | $127.0M | $103.4M | $183.2M | $273.6M | $261.6M | $167.0M | $3.5M | $-71.2M |